Q2 2023 13F Holders as of 6/30/2023
-
Type / Class
-
Equity / COM
-
Number of holders
-
24
-
Total 13F shares, excl. options
-
1.27M
-
Shares change
-
+118K
-
Total reported value, excl. options
-
$5.68M
-
Value change
-
+$521K
-
Put/Call ratio
-
0.73
-
Number of buys
-
15
-
Number of sells
-
-5
-
Price
-
$4.48
Significant Holders of Gain Therapeutics, Inc. - COM (GANX) as of Q2 2023
30 filings reported holding GANX - Gain Therapeutics, Inc. - COM as of Q2 2023.
Gain Therapeutics, Inc. - COM (GANX) has 24 institutional shareholders that have filed 13F forms with the Securities Exchange Commission (SEC).
These institutions hold a total of 1.27M shares
.
Largest 10 shareholders include GREENLIGHT CAPITAL INC (547K shares), GEODE CAPITAL MANAGEMENT, LLC (139K shares), CM Management, LLC (90K shares), SUSQUEHANNA INTERNATIONAL GROUP, LLP (69.8K shares), VANGUARD GROUP INC (64.1K shares), PRELUDE CAPITAL MANAGEMENT, LLC (58.1K shares), RENAISSANCE TECHNOLOGIES LLC (47.6K shares), BRIDGEWAY CAPITAL MANAGEMENT, LLC (46.1K shares), CITADEL ADVISORS LLC (36.2K shares), and RAYMOND JAMES & ASSOCIATES (33.4K shares).
This table shows the top 24 institutional shareholders of the company equity. This data is sourced directly from the SEC via 13F filings.
| Investor |
Option |
Weight % |
Change % |
Value $ |
* Price $ |
Shares |
Share Change |
Activity |
Report Period |
* Reported Price is the price of the security as of the portfolio date. This value is significant in that it is the last known price at which the security was still held.
An asterisk sign (*) next to the price indicates that the price is likely invalid.